The word gradient (from grade) means the inclination of a surface along a given direction. In MRI, gradient stands for gradient field and/or gradient coil. Inside the main magnet are three gradient coils located, which produce the desired gradient (magnetic) fields. These fields are used to alter (collectively and sequentially) the influence of the static magnetic field B0 on the imaged object by inc- or decreasing the field strength and changing the direction. Through this influence selective spatial excitation and spatial encoding (each voxel resonate at a different frequency) is possible. Gradients are also utilized in another way for fast imaging sequences.

See also Slew Rate and Duty Cycle.

Current carrying coils designed to produce a desired magnetic field gradient (so that the magnetic field will be stronger in some locations than others).
Proper design of the size and configuration of the coils is necessary to produce a controlled and uniform gradient. Three paired orthogonal current-carrying coils located within the magnet that are designed to produce desired gradient magnetic fields, which collectively and sequentially are superimposed on the main magnetic field (B0) so that selective spatial excitation of the imaging volume can occur.
Gradients are also used to apply reversal pulses in some fast imaging techniques. Gradient coils in general vary the main magnetic field, so that each signal can be related to an exact location. The gradient coil configuration for the z-axis consists of e.g., Helmholtz pair coils, and of paired saddle coils for the x- and y-axis.

See also the related poll result: 'Most outages of your scanning system are caused by failure of'

[H₀] Conventional symbol historically used for the constant magnetic field in an MR system; it is physically more correct to use B0.

Lumirem® belongs to the negative oral contrast agents (same as GastroMARK®, another brand name for ferumoxsil). Lumirem® is used to distinguish the loops of the bowel from other abdominal structures and physiology. When Lumirem® is ingested, it flows through and darkens the stomach and the small intestine in 30 to 45 minutes. By more clearly identifying the intestinal loops, Lumirem® improves visualization of adjacent abdominal tissues such as the pancreas.
Additionally, in Europe Lumirem® is approved for rectal administration to delineate the lower intestinal system.

Short name: MP 2269, chemical compound: 4-pentyl-bicyclo [2.2.2] octan-1-carboxyl-di-L-aspartyllysine-DTPA, central moiety: Gd2+, relaxivity: r1=6.2, B0=1.0 T
An intravascular positive enhancing MRI contrast agent under development (preclin.) for MR angiography.